Oragenics Making ‘Great Progress’ Enrolling Patients in Oral Mucositis Clinical Trial (Proactive)

Oragenics Making ‘Great Progress’ Enrolling Patients in Oral Mucositis Clinical Trial

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, announced that they are making great progress enrolling patients in their clinical trial.

“We are primarily enrolling patients in our oral mucositis program AG013 and it is nice to say that we are almost done. We are up to about 185 of 200 patients and we are making great progress,” said Alan Joslyn, Ph.D., Oragenics president and CEO.

Learn more about Oragenics Making ‘Great Progress’ Enrolling Patients in Oral Mucositis Clinical Trial.
X